Clinical Considerations for <em>RET</em> Fusion–Positive NSCLC
Listen to lung cancer experts Joshua Bauml, MD, a molecular oncologist, and Dara L. Aisner, MD, PhD, a molecular pathologist, discuss clinical considerations for patients with RET fusion–positive NSCLC, including testing for RET fusions, using new selective RET inhibitors in these patients, and the importance of interdisciplinary communication.
Decera Clinical Education Oncology Podcast · Dara L. Aisner MD PhD, Joshua Bauml MD
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this podcast episode, listen to lung cancer experts Joshua Bauml, MD, a medical oncologist, and Dara L. Aisner, MD, PhD, a molecular pathologist, discuss clinical considerations for patients with RET fusion–positive NSCLC, with topics including:
- Optimal testing for RET fusions
- DNA NGS vs RNA NGS
- Molecular testing workflows
- Using new selective RET inhibitors to treat patients with RET fusion–positive NSCLC
- Common toxicities with new selective RET inhibitors
- Interdisciplinary communication between medical oncologists and pathologists
Presenters:
Dara L. Aisner, MD, PhD
Associate Professor
Department of Pathology
Director, Molecular Pathology
University of Colorado
Aurora, Colorado
Joshua Bauml, MD
Assistant Professor of Medicine
Division of Hematology/Oncology
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania
Link to full program, including associated downloadable slidesets:
https://bit.ly/2Fsq9Wv
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.